Clin2
NCT05199194Possibly a fitRecruiting

Clot-busting before or during procedure for acute stroke

Stroke, IschemicStroke, Acute

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This study compares two treatment approaches for a stroke caused by a blocked brain artery: doing a procedure to remove the clot alone versus giving an IV clot-busting medicine first (tenecteplase). It aims to see which approach works better and is safest for improving recovery.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
398 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You had an acute ischemic stroke and can get an IV clot-busting drug within 4.5 hours
  • Your basic function before the stroke was very good (no more than mild problems), and you are age 18 to 85
  • Your stroke is severe enough at baseline (NIHSS score 6 or higher) and you are randomized within 4.5 hours of last being well
  • Imaging shows a blockage in a key artery (ICA or the main/proximal middle brain artery segments) that can be treated by a clot-removal procedure
  • You can sign consent (or a legally allowed representative can)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06658197Recruiting· Phase 3
Comparing a new clot-busting drug for severe stroke

This study tests a medication called tenecteplase, given before a procedure to remove a large blood clot in the brain. It may help people who have had a severe stroke within the last 4.5 hours.

Beijing, Beijing Municipality
NCT06320431Recruiting· Phase 3
Clot-busting drug for disabling stroke within 4.5 hours

This trial tests a clot-busting drug called tenecteplase for people having a disabling ischemic stroke (a clot blocking blood flow to the brain). It aims to see if the drug can help improve recovery when given within 4.5 hours of symptoms starting.

Sydney, Barangaroo
NCT05199662Recruiting· Phase 3
IV clot-busting medicine for stroke when standard options don’t fit

This trial tests whether giving IV TNK (tenecteplase) plus standard stroke care can improve outcomes in some people who have a new stroke but cannot get alteplase (another clot-busting drug) and do not have a large blocked artery that can be treated with a procedure. It’s meant for strokes with “mismatch” findings on scans that suggest salvageable brain tissue.

Porto Alegre, Rio Grande do Sul
NCT06987305Recruiting· Phase 3
Clot-busting medication before clot removal for late-arriving stroke

This trial tests whether adding a clot-busting medication (rhTNK-tPA) before a clot-removal procedure (thrombectomy) can improve outcomes for people who have a moderate-to-severe stroke and arrive at the hospital 4.5 to 24 hours after symptoms start. It's for those with a large artery blockage but still enough brain tissue that can be saved.

Wuhan, Hubei
NCT07302854Recruiting· Phase 2/Phase 3
Clot-busting medicine for medium vessel strokes

This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.

Wuhan, Hubei
NCT06559436Recruiting
Extending window for clot-busting drug in medium vessel stroke

This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.

Hefei, Anhui

Hear when a new Stroke, Acute trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.